Anticancer agent 265

• Description :

  Anticancer agent 265 (compound 1) is an anticancer compound. Anticancer agent 265 exhibits in vitro anticancer activity against three human bone cancer lines, U2OS, Saos-2, and GC9811, with IC50 values ​​of 13.1, 11.7, and 14.6 μM, respectively[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Drug Derivative

• Related Pathways :

  Others

• Field of Research :

  Cancer

• Purity :

  99.74

• Smiles :

  O=C1N(C2=CC=C(N3CCN(C4=CC=C(O)C=C4)CC3)C=C2)C=NN1[C@@H](CC)[C@@H](OCC5=CC=CC=C5)C

• Molecular Formula :

  C30H35N5O3

• Molecular Weight :

  513.63

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]G Lv, et al. Synthesis, crystal structure, anti-bone cancer activity and molecular docking investigations of the heterocyclic compound 1- ((2S, 3S) -2- (benzyloxy) pentan-3-yl) -4- (4- (4- (4-hydroxyphenyl) piperazin-1-yl) phenyl) -1H-1, 2, 4-triazol-5 (4H) -one. Journal of Structural Chemistry 60.7 (2019) : 1173-1179.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [184177-83-1]